Along With Sales Across Regions And Categories, Perrigo’s Labor Shortage Concerns Grow
“The only thing that keeps me up at night right now is labor shortages,” says CEO Murray Kessler. He also notes growing trend of consumers responding to inflation by moving from national brands to lower-priced private label/store brand OTC drugs.
You may also be interested in...
Two days before flooding closed its Sturgis plant, Abbott announced it would import 1.1m pounds of powder formula to the US from its manufacturing facility in Spain.
HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.
HBW Insight speaks to HRA Pharma CEO David Wright about the company's recent UK Rx-to-OTC contraceptive pill switch, it's signifcance for the global women's health category and the implications for a similar switch the company is pursuing in the US.